APOA1 and atherosclerosis: Furthermore, studies have found that the cardiovascular drug perhexiline can induce the expression of KLF14 and increase blood HDL-C levels and cholesterol outflow ability by upregulating ApoA1 and ameliorating the development of atherosclerosis by targeting the KLF14 pathway [17].